Treatment strategies for NSCLC include chemotherapy regimens based on histology and targeted agents for patients who carry somatic activated oncogenes, such as epidermal growth factor receptor (EGFR) and translocated anaplastic lymphoma kinase (ALK). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.